Abiopharma

🔍 Boulding Mark Elliott (Executive)

Company: PTC THERAPEUTICS, INC. (PTCT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 17,000 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 120,901.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,266 shares of Common Stock at $39.42 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 123,167.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,123 shares of Common Stock at $74.92 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 122,044.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 1,035 shares of Common Stock at $76.1 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 121,009.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 108 shares of Common Stock at $76.79 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 120,901.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Acquired 42,500 shares of Stock Option (Right to Buy) at $76.74 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | equity_swap_involved: 0 | shares_owned_after: 42,500.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 2,266 shares of Stock Option (Right to Buy) at $39.42 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2033-01-04 | equity_swap_involved: 0 | shares_owned_after: 9,063.00 | transaction_form_type: 4 | Footnotes: F2, F7

Footnotes:

• F1: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.
• F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.
• F3: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $74.55 to $75.27 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
• F4: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.58 to $76.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
• F5: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.75 to $76.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
• F6: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.
• F7: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.